{
    "clinical_study": {
        "@rank": "67180", 
        "acronym": "RabOCT", 
        "arm_group": [
            {
                "arm_group_label": "OCT guided group", 
                "arm_group_type": "Experimental", 
                "description": "Patients randomized to this group will get the intravitreal injection of 0.5 mg ranibizumab if the morphological macular changes for recurrence of macular edema (microcystic changes with or without increase of central retinal thickness) will be detected by OCT."
            }, 
            {
                "arm_group_label": "Standard treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients randomized to this group will get the intravitreal injection of 0.5 mg ranibizumab according to the in SmPC defined re-treatment criteria (re-injection if decrease of BCVA will be detected)."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the trial is to evaluate the efficacy and safety of intravitreal injections of\n      ranibizumab for the treatment of macular edema due to BRVO if the re-treatment regimen is\n      guided by morphological macular changes detected by OCT compared to re-treatment according\n      to SmPC defined re-treatment criteria (in case of increase of CRT and concomitant decrease\n      of BCVA)."
        }, 
        "brief_title": "Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Branch Retinal Vein Occlusion", 
        "condition_browse": {
            "mesh_term": [
                "Macular Edema", 
                "Retinal Vein Occlusion"
            ]
        }, 
        "detailed_description": {
            "textblock": "In a prospective, randomized, interventional, controlled phase IIb  clinical the functional\n      results of treatment with ranibizumab in patients with macular edema due to branch retinal\n      vein occlusion when given according to morphological changes detected by OCT compared to\n      standard re-treatment criteria according to SmPC"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Recurrence of macular edema defined as any kind of fluid accumulation in the macula\n             (microcystic changes with or without increase of central retinal thickness) detected\n             by OCT in the month 1 to 6 after the last Lucentis injection without any decrease of\n             BCVA measured with ETDRS charts 2. Diagnosis of BRVO with macular edema treated with\n             at least three intravitreally applied injections of ranibizumab after the up-load\n             phase of treatment 3.  Age \u2265 18 years 4. Ability and willingness to attend all\n             scheduled visits and assessments 5. For sexually active women of childbearing\n             potential, use of an appropriate form of contraception (or abstinence) for the\n             duration of the study\n\n        Exclusion Criteria:\n\n          1. Macular edema due to another etiology than retinal vein occlusion (e.g. diabetic\n             maculopathy, uveitis, age related macular degeneration, Irvine-Gass syndrome)\n\n          2. Evidence upon examination of vitreoretinal interface disease (e.g., vitreomacular\n             traction, epiretinal membrane), either on clinical examination or OCT, thought to be\n             contributing to macular edema\n\n          3. Use of intraocular or periocular injection of steroids in the study eye (e.g.,\n             triamcinolone) prior to study entry\n\n          4. History of cerebral vascular accident, myocardial infarction, transient ischemic\n             attacks in last 6 months\n\n          5. Pregnancy (positive pregnancy test) or lactation\n\n          6. History of allergy to humanized antibodies or any component of the ranibizumab\n             formulation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01968239", 
            "org_study_id": "201200543910"
        }, 
        "intervention": {
            "arm_group_label": [
                "OCT guided group", 
                "Standard treatment"
            ], 
            "description": "comparison of different re-treatment criteria for intravitreal injection of ranibizumab", 
            "intervention_name": "Ranibizumab", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "BRVO", 
            "Macular edema", 
            "Ranibizumab", 
            "re-treatment"
        ], 
        "lastchanged_date": "October 18, 2013", 
        "location": {
            "contact": {
                "email": "Matus.Rehak@medizin.uni-leipzig.de", 
                "last_name": "Matus Rehak, MD, Ph.D.", 
                "phone": "+49-341-9721664"
            }, 
            "facility": {
                "address": {
                    "city": "Leipzig", 
                    "country": "Germany", 
                    "zip": "04103"
                }, 
                "name": "Department of Ophthalmology, University Leipzig"
            }, 
            "investigator": {
                "last_name": "Matus Rehak, MD, Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Controlled Interventional Phase 2b (Proof of Concept) Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Ranibizumab Guided by Morphological Changes Documented by Optical Coherence Tomography (OCT) in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)", 
        "overall_contact": {
            "email": "Matus.Rehak@medizin.uni-leipzig.de", 
            "last_name": "Matus Rehak, MD, Ph.D.", 
            "phone": "+49-341-9721664"
        }, 
        "overall_contact_backup": {
            "email": "claudia.jochmann@medizin.uni-leipzig.de", 
            "last_name": "Claudia Jochmann, MD", 
            "phone": "+49-341-9721650"
        }, 
        "overall_official": {
            "affiliation": "Department of Ophthalmology, University of Leipzig, Germany", 
            "last_name": "Matus Rehak, MD, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "change of best corrected visual acuity (BCVA) measured in ETDRS letters", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01968239"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Leipzig", 
            "investigator_full_name": "PD Dr. habil. Matus Rehak", 
            "investigator_title": "MD, Ph.D", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Central retinal thickness (CRT)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Number of applied ranibizumab injections", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "\u2022 Rates of patients developing a neovascularisation of the retina/ anterior segment", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Assessment of safety: serious adverse events/ reactions; AEs/ARs", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "University of Leipzig", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Leipzig", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}